Insight

Exploring New Avenues in Breast Cancer Treatment – The Babak Lab

The Babak Lab/LinkedIn

Nov 13, 2024, 16:02

Exploring New Avenues in Breast Cancer Treatment – The Babak Lab

The Babak Lab shared a post on LinkedIn:

“Clinical Monday: Exploring New Avenues in Breast Cancer Treatment.

A recent study, led by Hoffmann-La Roche, is investigating the combination of inavolisib with palbociclib and fulvestrant for treating PIK3CA-mutant, hormone receptor-positive, HER2-negative breast cancer.

This randomized, double-blind, placebo-controlled Phase III trial (ClinicalTrials.gov ID: NCT04191499) primarily aims to assess progression-free survival (PFS), providing insights into whether adding inavolisib extends the time before disease progression compared to a standard treatment combination.

Key primary and secondary measures:

Primary Outcome

PFS, defined by the time to progression or death.

Secondary Outcomes

Include overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and health-related quality of life indicators like pain and physical function.

The study is ongoing, with interim results anticipated in 2024. The findings could add a valuable option for those whose cancer progressed despite prior therapies, potentially extending quality life and survival time.

What are your thoughts on emerging combination therapies in oncology? Drop a comment, like, or share to help spread the conversation around innovative approaches in cancer care.”

Maria Babak, Head of The Babak Lab, shared this post, adding:

“This study is an important advancement for patients with PIK3CA-mutant, HR-positive, HER2-negative breast cancer, especially those with limited options after progression.

Combining inavolisib with standard treatments like palbociclib and fulvestrant could be a game-changer in delaying progression. Looking forward to seeing the impact of this combination on both survival outcomes and quality of life measures.”

More posts featuring The Babak Lab and Maria Babak.

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases. She received the Yvonne Award by OncoDaily in the “mentorship” category.